Quantitative analysis and pharmacokinetics study of integrin antagonist AP25 in rat plasma.

Yongbing Li,Hanmei Xu,Jialiang Hu,Fengguo Zhang,Zhendong Liu,Chi Zhang,Yongjing Yang,Chunyan Pu,Linqiu Huang,Xin Wen
DOI: https://doi.org/10.2174/0929866511320050012
2013-01-01
Protein and Peptide Letters
Abstract:BALB/cmice were immunized by highly immunogenic recombinant proteins containing amino acid sequence of integrin antagonist AP25. Antibody against AP25 was prepared and purified by affinity chromatography. An indirect enzyme-linked immunosorbent assay for qualitative analysis of AP25 in rat plasma samples was successfully established. The assay was successfully applied to determine the pharmacokinetic parameters of AP25 in SD rats by inavenous administration of AP25 and then the rat plasma protein binding of AP25 were determined in vitro. In order to investigate the specificity of ELISA for detection of prototype AP25 in plasma, the proportion of AP25 prototype drug in the ELISA signal value was validated by HPLC. These results can serve as valuable future clinical trials.
What problem does this paper attempt to address?